Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 27, 2023 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
January 09, 2023 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
January 03, 2023 07:00 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
December 27, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 22, 2022 07:00 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

STAMFORD, Conn., Nov. 22, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
November 03, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – –...
September 29, 2022 06:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
September 10, 2022 10:30 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA Planned for...
September 07, 2022 09:56 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
September 07, 2022 09:55 ET | Source: SpringWorks Therapeutics, Inc.

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development...